Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glycoprotein hormones, alpha polypeptide | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Toxoplasma gondii | intraflagellar transport protein 172, putative | glycoprotein hormones, alpha polypeptide | 116 aa | 94 aa | 26.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trichomonas vaginalis | CAMK family protein kinase | 0.0614 | 0.5955 | 1 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0614 | 0.5955 | 1 |
Onchocerca volvulus | Serine\/threonine kinase homolog | 0.0614 | 0.5955 | 0.5 |
Trypanosoma cruzi | polo-like protein kinase, putative | 0.0614 | 0.5955 | 0.5 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0614 | 0.5955 | 1 |
Echinococcus granulosus | serine:threonine protein kinase PLK1 | 0.0614 | 0.5955 | 1 |
Loa Loa (eye worm) | PLK/PLK1 protein kinase | 0.0614 | 0.5955 | 0.5 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0614 | 0.5955 | 1 |
Brugia malayi | serine/threonine-protein kinase plk-2 | 0.0614 | 0.5955 | 0.5 |
Echinococcus multilocularis | serine:threonine protein kinase PLK1 | 0.0614 | 0.5955 | 1 |
Trypanosoma cruzi | polo-like protein kinase, putative | 0.0614 | 0.5955 | 0.5 |
Leishmania major | protein kinase, putative,polo-like protein kinase, putative | 0.0614 | 0.5955 | 0.5 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0614 | 0.5955 | 1 |
Trypanosoma brucei | polo-like protein kinase | 0.0614 | 0.5955 | 0.5 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0614 | 0.5955 | 1 |
Giardia lamblia | Kinase, PLK | 0.0614 | 0.5955 | 0.5 |
Entamoeba histolytica | serine/threonine protein kinase, putative | 0.0614 | 0.5955 | 0.5 |
Trichomonas vaginalis | CAMK family protein kinase | 0.0614 | 0.5955 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 2.2387 uM | PubChem BioAssay. qHTS for Activators of Integrin-Mediated Alleviation for Muscular Dystrophy. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 4.1475 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 23.1093 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PubChem BioAssay. Inhibitors of Secretory Acid Sphingomyelinase (S-ASM): qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 32.6427 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of RanGTP induced Rango (Ran-regulated importin-beta cargo) - Importin beta complex dissociation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID540262] | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Potency (functional) | 125.8925 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.